Lucas Burneo, José Julio DeNavarro, J. L.,Rubio Langre, SoniaVignolo, P. E.Asis, V. C.González Gómez, FernandoRodríguez Fernández, Casilda2024-12-102024-12-102008de Lucas, J. J., Navarro, J. L., Rubio, S., Vignolo, P. E., Asis, V. C., González, F., & Rodríguez, C. (2008). Pharmacokinetic behaviour of enrofloxacin in greater rheas following a single-dose intramuscular administration. Veterinary journal (London, England : 1997), 175(1), 136–138. https://doi.org/10.1016/j.tvjl.2006.11.0071090-023310.1016/J.TVJL.2006.11.007https://hdl.handle.net/20.500.14352/112368The pharmacokinetic behaviour of enrofloxacin in greater rheas was investigated after intramuscular (IM) administration of 15 mg/kg. Plasma concentrations of enrofloxacin and its active metabolite, ciprofloxacin, were determined by high performance liquid chromatography. Enrofloxacin peak plasma concentration (Cmax = 3.30 ± 0.90 μg/mL) was reached at 24.17 ± 9.17 min. The terminal half-life (t1/2λ) and area under the curve (AUC) were 2.85 ± 0.54 h and 4.18 ± 0.69 μg h/mL, respectively. The AUC and Cmax for ciprofloxacin were 0.25 ± 0.06 μg/mL and 0.66 ± 0.16 μg h/mL, respectively. Taking into account the values obtained for the efficacy indices, an IM dose of 15 mg/kg of enrofloxacin would appear to be adequate for treating infections caused by highly susceptible bacteria (MIC90 < 0.03 μg/mL) in greater rheas.engjournal articlehttps://doi.org/10.1016/J.TVJL.2006.11.00717303451metadata only access615PharmacokineticEnrofloxacinCiprofloxacinRheaIntramuscularCiencias Biomédicas32 Ciencias Médicas